SCHEDULE 13G/A: Vanguard Group Updates Passive Stake in Capricor Therapeutics, Holding 4.95% of Common Stock

The Vanguard Group has filed an amended Schedule 13G, disclosing its passive beneficial ownership of 4.95% of Capricor Therapeutics Inc.'s common stock as of March 31, 2025.

Summary

• The Vanguard Group, an investment adviser, filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Capricor Therapeutics Inc.
• As of March 31, 2025, Vanguard beneficially owns an aggregate of 2,263,991 shares of Capricor Therapeutics Inc. common stock.
• This ownership represents 4.95% of the total class of Capricor Therapeutics Inc. common stock.
• Vanguard holds 0 shares with sole voting power, 49,251 shares with shared voting power, 2,171,616 shares with sole dispositive power, and 92,375 shares with shared dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing passive beneficial ownership. It contains factual information about shareholdings and does not provide operational or financial performance data, thus maintaining a neutral sentiment.

Positives

• The continued holding by a major institutional investor like The Vanguard Group, even if passive, can be viewed as a sign of long-term confidence in Capricor Therapeutics.
• The filing confirms that Vanguard's interest is solely for investment purposes and not to influence control, which can provide stability regarding the company's governance structure.

Negatives

• The beneficial ownership percentage of 4.95% is below the 5% threshold, meaning Vanguard is not considered a significant control person and has limited direct influence on corporate governance decisions.

Risks

• The document itself does not detail operational or financial risks for Capricor Therapeutics; it is solely a disclosure of beneficial ownership.
• From the perspective of this filing, the primary 'risk' is that Vanguard's stake is below the 5% threshold, limiting their ability to directly influence the company's strategic direction or management.

Future Outlook

No forward-looking statements or guidance regarding Capricor Therapeutics' future performance or strategic direction are provided in this beneficial ownership disclosure.

Management Comments

• "The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein."
• "No one other person's interest in the securities reported herein is more than 5%."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a routine disclosure by a major institutional asset manager, The Vanguard Group, indicating its passive investment in Capricor Therapeutics, a company likely operating in the biotechnology or pharmaceutical sector. Such disclosures are common and reflect the ongoing portfolio management activities of large investment firms across various industries.

Comparison to Industry Standards

• This document is a standard regulatory filing (Schedule 13G) for disclosing beneficial ownership below 5%. It does not contain information that allows for a comparison of Capricor Therapeutics' operational or financial results against industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The continued, albeit passive, investment by a large institutional investor like Vanguard may provide a degree of stability and confidence to other shareholders.

Next Steps

• No specific future actions, events, or milestones for Capricor Therapeutics are mentioned in this beneficial ownership filing.

Key Dates

Keywords

Capricor Therapeutics, Vanguard Group, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Passive Investment, SEC Filing